Author:
Rugo H.S.,Hortobagyi G.N.,Yao J.,Pavel M.,Ravaud A.,Franz D.,Ringeisen F.,Gallo J.,Rouyrre N.,Anak O.,Motzer R.
Funder
Novartis Pharmaceuticals Corporation
Reference12 articles.
1. Mammalian target of rapamycin inhibitor-associated stomatitis;Boers-Doets;Future Oncol,2013
2. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients;Martins;Oral Oncol,2013
3. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients;Sonis;Cancer,2004
4. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer;Baselga;N Engl J Med,2012
5. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial;Andre;Lancet Oncol,2014
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献